In the BioHarmony Drug Report Database
Thioguanine
Thioguanine (thioguanine) is a small molecule pharmaceutical. Thioguanine was first approved as Thioguanine on 1982-01-01. It is used to treat basophilic leukemia acute, bcr-abl positive chronic myelogenous leukemia, eosinophilic leukemia acute, neutrophilic leukemia chronic, and psoriasis in the USA. The pharmaceutical is active against inosine-5′-monophosphate dehydrogenase 2 and inosine-5′-monophosphate dehydrogenase 1. In addition, it is known to target 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine diphosphokinase.
Trade Name
|
Thioguanine |
|---|---|
Common Name
|
thioguanine |
ChEMBL ID
|
CHEMBL727 |
Indication
|
basophilic leukemia acute, bcr-abl positive chronic myelogenous leukemia, eosinophilic leukemia acute, neutrophilic leukemia chronic, psoriasis |
Drug Class
|
Image (chem structure or protein)